Market Place
Sourcing Support
Inmagene Hosts KOL Event On OX40L Inhibition For Alopecia
09 Oct 2024 //
GLOBENEWSWIRE
Inmagene Announces Positive Results of a MAD Study, Reversible BTK Inhibitor
27 Jun 2024 //
GLOBENEWSWIRE
Inmagene Completes Phase 2a Trial Of IMG-007 In Alopecia Areata Patients
07 May 2024 //
GLOBENEWSWIRE
Inmagene`s IMG-007 Shows Positive Interim Atopic Dermatitis Data
06 May 2024 //
GLOBENEWSWIRE
Inmagene Exercises Option to Obtain Worldwide License for IMG-007 and IMG-004
02 Feb 2024 //
PR NEWSWIRE
Inmagene Doses First Patient in Phase 2a Trial of IMG-007
13 Oct 2023 //
PR NEWSWIRE
Inmagene announces formation of Celexor Bio based on its anti-ILT7 mAb
21 Sep 2023 //
PR NEWSWIRE
Inmagene`s anti-OX40 mAb demonstrated an extended half-life in a Phase I study
18 Aug 2023 //
PR NEWSWIRE
Inmagene`s OX40 mAb enters POC study in Atopic Dermatitis
15 Aug 2023 //
PR NEWSWIRE
Inmagene reports positive topline data from IMG-004 Phase I study
01 May 2023 //
CIINICAL TRIALS ARENA
Inmagene receives IND clearance for IMG-008, a long-acting IL-36R mAb
06 Feb 2023 //
PR NEWSWIRE
Inmagene and HUTCHMED Announce First Participants in Global PI Trial of IMG-007
05 Jul 2022 //
PRNEWSWIRE
ACELYRIN, Affibody. Inmagene Biopharma Announce Data from PII Trial of Izokibep
03 Jun 2022 //
PRNEWSWIRE
FDA Clears IND of Inmagene`s 3rd Gen BTK Inhibitor for Immunological Diseases
15 May 2022 //
PRNEWSWIRE
Inmagene Receives FDA`s IND Clearance for OX40 Antagonist
30 Apr 2022 //
PRNEWSWIRE
ACELYRIN, Affibody & Inmagene Shows +ve Interim Results from Phase 2 of Izokibep
13 Dec 2021 //
PRNEWSWIRE
Inmagene files two international patent applications
17 Nov 2021 //
PRNEWSWIRE
Affibody and Inmagene announce First Patient Dosed in Phase 2 ASPIRE Trial
25 Aug 2021 //
PRESS RELEASE
Affibody and Inmagene announce IND Clearance for izokibep (ABY-035)
09 Mar 2021 //
MYNEWSDESK
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.